


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

				Substitution for form 1449A/PTO	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/628,141
				Filing Date	July 24, 2003
				First Named Inventor	Srinivas G. Rao
				Group Art Unit	1614
				Examiner Name	
Sheet	1	of	6	Attorney Docket Number	CYPR 101

[illegible][illegible]

Examine Signature	<i>N. Look</i>	Date Considered	12/2/03
----------------------	----------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.


¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.**



Please type a plus sign (+) inside this box →



PTO/S&D/8A (10-88)
Approved for use through 10/31/99. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/628,141		
		Filing Date	July 24, 2003		
		First Named Inventor	Srinivas G. Rao		
		Group Art Unit	1614		
		Examiner Name			
Sheet	2	of	6	Attorney Docket Number	CYPR 101

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
h		AKIL & LIEBESKIND, "Monoaminergic mechanisms of stimulation-produced analgesia," <i>Brain Res.</i> 94: 279-296 (1975).	
h		BAKER & GREENSHAW, "Effects of long-term administration of antidepressants and neuroleptics on receptors in the central nervous system," <i>Cell Molec. Neurobiol.</i> 9(1): 1-44 (1989).	
h		BECK, ed., <i>Depression: Clinical, Experimental and Theoretical Aspects</i> , Hoeber: New York (1967).	
h		BERGE, et al., "Attenuation of morphine-induced analgesia by p-chlorophenylalanine and p-chloroamphetamine: test-dependent effects and evidence for brainstem 5-hydroxytryptamine involvement," <i>Brain Res.</i> 271: 51-64 (1983).	
h		BLIER & DEMONTIGNY, "Current advances and trends in the treatment of depression," <i>Trends Pharmacol. Sci.</i> 15: 220-226 (1994).	
h		BROWN, et al., "Depression: Distress or disease? Some epidemiological consideration," <i>Br. J. Psychiatry</i> 147: 612-622 (1985).	
h		BUCKETT, et al., "The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation," <i>Prog. Neuro-Psychopharmacol. & Biol. Psychiatry</i> 12: 575-584 (1988).	
h		DAVIDSON, et al., "Atypical depression," <i>Arch. Gen. Psychiatry</i> 39: 527-534 (1982).	
h		DELGADO, et al., "Serotonin function and the mechanism of antidepressant action," <i>Arch. Gen. Psychiatry</i> 47: 411-418 (1990).	
h		DEPREZ, et al., "Which bioequivalence study for a racemic drug? Application to milnacipran," <i>Eur. J. Drug Metab. Pharmacokinet.</i> 23(2): 166-171 (1998).	

Examiner's Signature	<i>[Signature]</i>	Date Considered	12/2/05
----------------------	--------------------	-----------------	---------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-88)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/628,141		
		Filing Date	July 24, 2003		
		First Named Inventor	Srinivas G. Rao		
		Group Art Unit	1614		
		Examiner Name			
Sheet	3	of	6	Attorney Docket Number	CYPR 101

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
W		DOAN & WADDEN, "Relationships between depressive symptoms and descriptions of chronic pain," <i>Pain</i> 36: 75-84 (1989).	
W		DOYLE & HU, "A new enantioselective synthesis of minalcipran and an analogue by catalytic asymmetric cyclopropanation," <i>Adv. Synth. Catal.</i> 343(3): 299-302 (2001).	
W		DWORKIN, et al., "Predicting treatment response in depressed and non-depressed chronic pain patients," <i>Pain</i> 24: 343-353 (1986).	
W		FULLER & WONG, "Effects of antidepressants on uptake and receptor systems in the brain," <i>Prog Neuro-psychopharmacol. & Biol. Psychiatry</i> 9: 485-490 (1985).	
✓		HALEY, et al., "Depression in chronic pain patients: relation to pain, activity, and sex differences," <i>Pain</i> 23: 337-343 (1985).	
		JOYCE, et al., "Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline," <i>Australian & NZ J. Psychiatry</i> 36: 384-391 (2002).	
W		KERNS & HAYTHORNTWHAITE, "Depression among chronic pain patients: cognitive-behavioral analysis and effect on rehabilitation outcome," <i>J. Consult. Clin. Psychol.</i> 56: 870-876 (1988).	
W		KRISHNAN, et al., "Depression as a psychopathological disorder in chronic pain," in <i>Chronic Pain</i> (France, et al., eds.) American Psychiatric Press: Washington, DC, pp. 194-218 (1988).	
W		KRISHNAN, et al., "Chronic pain and depression. II. Symptoms of anxiety in chronic low back pain patients and their relationship to subtypes of depression," <i>Pain</i> 22: 289-94 (1985).	
W		MORET, et al., "Biochemical profile of minalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug," <i>Neuropharmacology</i> 24(12): 1211-1219 (1985).	


Examiner's Signature	<i>W. Cook</i>	Date Considered	12/2/05
----------------------	----------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-88)
Approved for use through 10/31/99. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to furnish information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/628,141		
		Filing Date	July 24, 2003		
		First Named Inventor	Srinivas G. Rao		
		Group Art Unit	1614		
		Examiner Name			
Sheet	4	of	6	Attorney Docket Number	CYPR 101

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
N		OWENS & NEMEROFF, "Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter," <i>Clin. Chem.</i> 40: 288-95 (1995).	
h		PALMIER, et al., "Monoamine uptake inhibition by plasma from healthy volunteers after single oral doses of the antidepressant mirtazapine," <i>Eur. J. Clin. Pharmacol.</i> 37(3): 235-238 (1989).	
N		PAYKEL, et al., "Response to phenelzine and amitriptyline in subtypes of outpatient depression," <i>Arch. Gen. Psychiatry</i> 39: 1041-1049 (1982).	
		PAYKEL, et al., "Nosology of atypical depression," <i>Psychol. Med.</i> 13: 131-139 (1983).	
N		PORTER, et al., "Single dose comparison of bicitadine, codeine and placebo in postoperative pain," <i>Curr. Therapeutic Res.</i> 30 (1981).	
N		POST, et al., "Analgesia induced by 5-hydroxytryptamine receptor agonists is blocked or reversed by noradrenaline-depletion in rats," <i>Brain Res.</i> 363: 18-27 (1986).	
h		POTTER & MANJI, "Catecholamines in depression: an update," <i>Clin. Chem.</i> 40: 279-287 (1994).	
N		QUITKIN, et al., "Phenelzine and imipramine in mood reactive depressives," <i>Arch. Gen. Psychiatry</i> 46: 787-93 (1989).	
h		ROMANO & TURNER, "Chronic pain and depression: does the evidence support a relationship?" <i>Psychol. Bull.</i> 97: 18-34 (1985).	
h		ROTHSCHILD, "Biology of depression," <i>Med. Clin. NA</i> 72: 765-90 (1988).	


Examiner's Signature	<i>N. Cook</i>	Date Considered	12/2/05
----------------------	----------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-98)
Approved for use through 10/31/99. OMB 0551-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/628,141		
		Filing Date	July 24, 2003		
		First Named Inventor	Srinivas G. Rao		
		Group Art Unit	1614		
		Examiner Name			
Sheet	5	of	6	Attorney Docket Number	CYPR 101

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
K		SHUTO, et al., "(+/-)-(Z)-2-(aminomethyl)-1-phenylcyclopropanecarboxamide derivatives as a new prototype of NMDA receptor antagonists," <i>J. Med. Chem.</i> 38: 2964-2968 (1995).	
K		SHUTO, et al., "(1S,2R)-1-Phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC), a new class of NMDA-receptor antagonist: molecular design by a novel conformational restriction strategy," <i>Jpn. J. Pharmacol.</i> 85: 207-213 (2001).	
K		SHUTO, et al., "Synthesis and biological activity of conformationally restricted analogs of miltacipran: (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide, an efficient noncompetitive N-methyl-D-aspartic acid receptor antagonist," <i>J. Med. Chem.</i> 39: 4844-4852 (1996).	
K		SHUTO, et al., "Synthesis and biological activity of conformationally restricted analogues of miltacipran: (1S, 2R)-1-phenyl-2-[(R)-1-amino-2-propynyl]-N,N-diethylcyclopropanecarboxamide is a novel class of NMDA receptor channel blocker," <i>J. Med. Chem.</i> 41: 3507-3514 (1998).	
K		SHUTO, et al., "Synthesis of (+/-) and (-)-miltaciprans and their conformationally restricted analogs," <i>Tetrahedron Lett.</i> 37(5): 641-644 (1996).	
V		SIMSON, et al., "Infusion of a monoamine oxidase inhibitor into the locus coeruleus can prevent stress-induced behavioral depression," <i>Biol. Psychiatry</i> 21: 724-34 (1986).	
K		STEWART, et al., "Do age of onset and course of illness predict different treatment outcome among DSM IV depressive disorders with atypical features?" <i>Neuropsychopharmacol.</i> 26: 237-245 (2002).	
V		STROLIN-BENEDETTI, "Biochimie de la dépression et des antidépresseurs," <i>Encephale</i> . 8(5): 545-585 (1982).	
K		VETULANI & SULSER, "Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain," <i>Nature</i> 257: 495-496 (1975).	
K		VETULANI, et al., "A possible common mechanism of action of antidepressant treatments," <i>Naunyn-Schmiedeberg Arch Pharmacol</i> 293:109-114 (1976).	

Examiner's Signature		Date Considered	12/2/05
----------------------	--	-----------------	---------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-88)
Approved for use through 10/31/89. OMB 0551-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1985, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/628,141		
		Filing Date	July 24, 2003		
		First Named Inventor	Srinivas G. Rao		
		Group Art Unit	1614		
		Examiner Name			
Sheet	6	of	6	Attorney Docket Number	CYPR 101

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
V		VIAZZO, et al., "Microbiological transformations 34: enantioselective hydrolysis of a key-lactone involved in the synthesis of the antidepressant miltacipran," <i>Tetrahedron Lett.</i> 37(26): 4519-4522 (1996).	
h		WANG, et al., "The oral analgesic efficacy of bicifadine hydrochloride in postoperative pain," <i>J. Clin. Pharmacol.</i> 22: 160-164 (1982).	

Examiner's Signature		Date Considered	12/2/05
-------------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-88)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/628,141
				Filing Date	July 24, 2003
				First Named Inventor	Srinivas G. Rao
				Group Art Unit	1614
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	CYPR 101

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
IN		RUOFF, et al., "Depression in the patient with chronic pain," <i>J. Fam. Practice</i> 43 (Suppl 6): S25-S34 (1996), abstract only.	

Examiner's Signature		Date Considered	12/2/05
-------------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.